Latest Consumer Staples News

New Zealand Coastal Seafoods has strengthened its financial footing with a $100,000 convertible note investment from cornerstone backer Ilwella Pty Ltd, aiming to accelerate its sustainable growth plans.

Pure Foods Tasmania has expanded its Tasmanian Pâté distribution from 300 to 700 Coles stores nationally, driving a forecast 15% uplift in sales. Early orders in September surged more than tenfold, signaling strong consumer demand.

Aumake Limited has launched Bio-Basic Ergothioneine, marking the debut of its innovative capital-light incubation model aimed at scaling premium health brands with minimal upfront investment.

Hydralyte USA reports an 11% sales increase in Q3 2025, driven by strong summer demand and the launch of its innovative Hydralyte Plus Brain Support product featuring nootropics.

The Calmer Co (ASX – CCO) reported an impressive $8 million revenue for FY25, marking 86% year-over-year growth and positioning itself as a global leader in the emerging kava market. With expanding retail presence and strong US sales, the company is on track to break even in 2026.

The Calmer Co International Limited has reported its strongest quarterly revenue ever at $2.4 million, driven by robust Australian retail sales and expanding US market presence. The company is also advancing a $1.4 million convertible note to fuel growth and inventory expansion.

OMG Group Limited has reported a remarkable 114% year-on-year increase in net sales for Q1 FY26, driven by robust ecommerce growth and expanding retail partnerships.

Wellnex Life Limited reported a robust 40.5% revenue increase in FY25, driven by the full-year integration of Pain Away, while margin recovery gains momentum in the second half.

The Calmer Co. has secured $700,000 in the first tranche of a $1.4 million convertible note raise, welcoming US distributor Applied Food Sciences as a strategic investor to fuel its expanding wholesale presence.

Synlait Milk Limited reports a modest profit turnaround in FY25 and announces a major sale of its North Island assets to Abbott, aiming to reduce debt and sharpen its focus on core operations.

Synlait has agreed to sell its North Island assets to global healthcare giant Abbott for approximately US$178 million, marking a strategic reset focused on debt reduction and operational simplification. The deal, expected to close by April 2026, positions Synlait to concentrate on its South Island operations and explore new growth avenues.

Synlait Milk Limited reported an 11.7% rise in revenue to NZD 1.83 billion for the year ending July 2025, yet its net loss deepened sharply to nearly NZD 40 million, prompting a halt on dividends.